Trial Profile
Safety, pharmacokinetics and pharmacodynamics study of DS-9001A in healthy volunteers: A randomized, placebo-controlled, single-ascending dose study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2018
Price :
$35
*
At a glance
- Drugs DS 9001 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 31 Dec 2016 Status changed from recruiting to completed, according to Affibody year end report 2016.
- 23 Dec 2015 New trial record